Stay updated on Pembrolizumab in Untreated Extensive SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.

Latest updates to the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedCore content updated with new government-status notice and version 3.2.0; a specific resource entry (Small cell lung carcinoma) was deleted (v3.1.0).SummaryDifference4%
- Check19 days agoChange Detected- Updated the page version from v3.0.2 to v3.1.0. Minor overall impact, mainly reflects a version increment.SummaryDifference0.1%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedUpdated the page from v3.0.1 to v3.0.2; removed the Back to Top link as a minor UI cleanup. No changes to pricing, stock availability, or time slots.SummaryDifference0.2%
- Check41 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%
- Check48 days agoChange DetectedThe web page has undergone significant updates, including the addition of specific facility names and locations in Italy, as well as new drug names related to cancer treatment. Notably, previous entries related to lung cancer and various antineoplastic agents have been removed.SummaryDifference5%
- Check62 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab in Untreated Extensive SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.